Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Z A, Arlin"'
Autor:
Tauseef Ahmed, Paul Baskind, Monika Baier, Y. M. Peng, Eric J. Feldman, A. Mittelman, Z. A. Arlin, David S. Alberts, Patricia M. Plezia
Publikováno v:
Journal of Clinical Oncology. 11:2002-2009
PURPOSE To determine the maximally tolerated dose of mitoxantrone in combination with cytarabine in patients with acute leukemia and advanced phases of chronic myelogenous leukemia (CML), and to assess the pharmacokinetics of high-dose mitoxantrone i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b84f7d477aa008e6e1c808c0c7ee8d1
https://doi.org/10.1200/jco.1993.11.10.2002
https://doi.org/10.1200/jco.1993.11.10.2002
Publikováno v:
Cancer Immunology Immunotherapy. 35:331-334
ImuVert, a new biological response modifier, was evaluated for toxicity and potential efficacy in patients with advanced cancer. This agent consists of sized, labile, natural membrane vesicles associated with ribosomes derived from Serratia marcescen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6896b93003733c7a84a74538f2d6493b
https://doi.org/10.1007/bf01741146
https://doi.org/10.1007/bf01741146
Autor:
P H, Wiernik, P L, Banks, D C, Case, Z A, Arlin, P O, Periman, M B, Todd, P S, Ritch, R E, Enck, A B, Weitberg
Publikováno v:
Blood. 79:313-319
The purpose of this study was to determine the relative merits of idarubicin and daunorubicin in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated adults with AML aged 15 years or more who were randomized to rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2402039eb256b91850545ae38e88d40
https://doi.org/10.1182/blood.v79.2.313.bloodjournal792313
https://doi.org/10.1182/blood.v79.2.313.bloodjournal792313
Autor:
Z. A. Arlin, Tauseef Ahmed
Publikováno v:
Blood. 79:2492-2494
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d3b289d6cbb9045d1df5fa5366c0299
https://doi.org/10.1182/blood.v79.9.2492.bloodjournal7992492b
https://doi.org/10.1182/blood.v79.9.2492.bloodjournal7992492b
Publikováno v:
Leukemia. 10(1)
Current anti-leukemic chemotherapy in patients with myelodysplastic syndromes (MDS) and MDS evolving to acute myeloid leukemia (AML) is associated with low response rates and high treatment-related toxicity. Homoharringtonine (HHT) is a novel cephalo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::38324043ee0faa6e88c4f1e056134e61
https://pubmed.ncbi.nlm.nih.gov/8558935
https://pubmed.ncbi.nlm.nih.gov/8558935
Autor:
J E, Kolitz, S J, Kempin, A, Schluger, G Y, Wong, E, Berman, S, Jhanwar, Z A, Arlin, T, Gee, B D, Clarkson
Publikováno v:
Seminars in oncology. 19(3 Suppl 9)
Suppression or eradication of the Philadelphia (Ph1) chromosome has been a major goal in the therapy of chronic myelogenous leukemia (CML). Variable levels of Ph1 chromosome negativity have been achieved using interferon-alfa, busulfan, combination c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::acc69ec0e9c519fdee9cecfd9cfe625c
https://pubmed.ncbi.nlm.nih.gov/1641654
https://pubmed.ncbi.nlm.nih.gov/1641654
Autor:
Z A, Arlin, T, Ahmed
Publikováno v:
Blood. 79(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6a32dc29d8a957e25bc5531f23f36563
https://pubmed.ncbi.nlm.nih.gov/1571564
https://pubmed.ncbi.nlm.nih.gov/1571564
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia
Autor:
C. Puccio, Stuart M. Lichtman, Morton Coleman, A. Mittelman, Richard T. Silver, P. Arnold, Daniel R. Budman, Z. A. Arlin, Tauseef Ahmed, E. J. Feldman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(9)
Using a loading dose/continuous infusion schedule, fludarabine phosphate was administered to 51 patients with previously treated chronic lymphocytic leukemia (CLL). All patients had evidence of active disease, and the majority had advanced Rai stages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865cc6124f993f42517c4808ac41ea74
https://pubmed.ncbi.nlm.nih.gov/1714949
https://pubmed.ncbi.nlm.nih.gov/1714949
Autor:
Z A, Arlin, E J, Feldman, L R, Finger, T, Ahmed, A, Mittelman, P, Cook, C, Puccio, P, Baskind, P, Arnold, E D, Razis
Publikováno v:
Leukemia. 5(8)
Mitoxantrone is effective in the treatment of acute myelogenous leukemia and, in combination with either vincristine-prednisone or cytarabine (HiDAc), it is also effective in acute lymphoblastic leukemia (ALL). As mitoxantrone exhibits a steep dose-r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3671c8ba808c9860b9680cbd3c0ac6b2
https://pubmed.ncbi.nlm.nih.gov/1886423
https://pubmed.ncbi.nlm.nih.gov/1886423
Publikováno v:
Leukemia. 4(11)
The selection of optimal treatment among the alternatives that are available is especially difficult in blastic phase of chronic myeloid leukemia (blCML) because of the absence of universally agreed upon criteria for the diagnosis of this phase and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::66f177d061e243a278b8869df2fab2ab
https://pubmed.ncbi.nlm.nih.gov/2232887
https://pubmed.ncbi.nlm.nih.gov/2232887